Table 6.

Analysis of pro- and anti-inflammatory markers (mortality)

Pro- and Anti-Inflammatory MarkersPatients Alive at 1 yr, d0Patients Dead at 1 yr, d0P ValuePatients Alive at 1 yr, d3Patients Dead at 1 yr, d3P Value
MIF, median (Q1, Q3), pg/ml16,227.0 (9778.2, 42,386.4)19,912.8 (9759.6, 46,549.8)0.8110,730.4 (4699.8, 16,597.2)9715.2 (5549.4, 24,394.2)0.63
IL-6, median (Q1, Q3), pg/ml982.5 (319.4, 2010.6)985.8 (329.4, 2033.5)0.92261.4 (100.9, 670.4)260.9 (89.7, 647.9)0.85
IL-8, median (Q1, Q3), pg/ml255.2 (94.1, 538.5)315.0 (94.8, 543.8)0.4361.7 (27.0, 110.6)46.0 (26.8, 125.7)0.90
IL-10, median (Q1, Q3), pg/ml42.8 (17.8, 120.4)55.8 (19.7, 251.0)0.2016.5 (9.7, 37.1)18.0 (9.6, 56.4)0.39
IL-18, median (Q1, Q3), pg/ml575.5 (309.7, 1220.5)589.8 (297.1, 1383.7)0.85564.9 (296.8, 1449.5)582.1 (310.6, 1708.7)0.51
TNFR-1, median (Q1, Q3), pg/ml1707.6 (1165.6, 2210.4)1745.2 (1122.4, 2507.3)0.761558.6 (951.6, 2493.6)2019.4 (1315.7, 3086.1)0.03
TNFR-2, median (Q1, Q3), pg/ml21,180.0 (14,411.3, 26,980.0)19,118.4 (12,878.4, 30,340.0)0.8120,220.0 (12,126.8, 31,420.0)25,290.0 (17,809.1, 40,475.0)0.03
  • d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.